IRIDEX (IRIX) Competitors $1.02 +0.03 (+2.59%) As of 11:56 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IRIX vs. HYPR, ICAD, CTSO, MBOT, TELA, APT, ECOR, APYX, INO, and TMDIFShould you be buying IRIDEX stock or one of its competitors? The main competitors of IRIDEX include Hyperfine (HYPR), iCAD (ICAD), Cytosorbents (CTSO), Microbot Medical (MBOT), TELA Bio (TELA), Alpha Pro Tech (APT), electroCore (ECOR), Apyx Medical (APYX), Inovio Pharmaceuticals (INO), and Titan Medical (TMDIF). These companies are all part of the "medical equipment" industry. IRIDEX vs. Hyperfine iCAD Cytosorbents Microbot Medical TELA Bio Alpha Pro Tech electroCore Apyx Medical Inovio Pharmaceuticals Titan Medical IRIDEX (NASDAQ:IRIX) and Hyperfine (NASDAQ:HYPR) are both small-cap computer and technology companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, community ranking, earnings and profitability. Does the media prefer IRIX or HYPR? In the previous week, IRIDEX had 1 more articles in the media than Hyperfine. MarketBeat recorded 9 mentions for IRIDEX and 8 mentions for Hyperfine. Hyperfine's average media sentiment score of 0.68 beat IRIDEX's score of 0.40 indicating that Hyperfine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IRIDEX 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hyperfine 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer IRIX or HYPR? IRIDEX presently has a consensus price target of $2.00, indicating a potential upside of 95.12%. Hyperfine has a consensus price target of $1.33, indicating a potential upside of 84.21%. Given IRIDEX's higher probable upside, analysts plainly believe IRIDEX is more favorable than Hyperfine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IRIDEX 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Hyperfine 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the MarketBeat Community prefer IRIX or HYPR? IRIDEX received 266 more outperform votes than Hyperfine when rated by MarketBeat users. Likewise, 63.11% of users gave IRIDEX an outperform vote while only 50.00% of users gave Hyperfine an outperform vote. CompanyUnderperformOutperformIRIDEXOutperform Votes27263.11% Underperform Votes15936.89% HyperfineOutperform Votes650.00% Underperform Votes650.00% Which has higher valuation & earnings, IRIX or HYPR? IRIDEX has higher revenue and earnings than Hyperfine. IRIDEX is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIRIDEX$48.43M0.35-$9.57M-$0.67-1.53Hyperfine$12.89M4.36-$44.24M-$0.56-1.29 Is IRIX or HYPR more profitable? IRIDEX has a net margin of -22.79% compared to Hyperfine's net margin of -309.42%. Hyperfine's return on equity of -57.54% beat IRIDEX's return on equity.Company Net Margins Return on Equity Return on Assets IRIDEX-22.79% -192.95% -33.97% Hyperfine -309.42%-57.54%-50.38% Which has more risk & volatility, IRIX or HYPR? IRIDEX has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Hyperfine has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Do insiders & institutionals believe in IRIX or HYPR? 20.1% of IRIDEX shares are owned by institutional investors. Comparatively, 15.0% of Hyperfine shares are owned by institutional investors. 7.3% of IRIDEX shares are owned by company insiders. Comparatively, 29.4% of Hyperfine shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryIRIDEX beats Hyperfine on 9 of the 17 factors compared between the two stocks. Remove Ads Get IRIDEX News Delivered to You Automatically Sign up to receive the latest news and ratings for IRIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IRIX vs. The Competition Export to ExcelMetricIRIDEXElectromedical equipment IndustryComputer SectorNASDAQ ExchangeMarket Cap$17.05M$3.31B$22.48B$7.68BDividend YieldN/A1.63%2.83%4.02%P/E Ratio-1.5314.4641.3918.55Price / Sales0.3543.421,962.1688.66Price / CashN/A44.0934.7334.64Price / Book1.743.355.954.11Net Income-$9.57M$94.03M$736.56M$247.18M7 Day Performance7.89%-3.66%-3.61%-4.05%1 Month Performance-25.72%-12.81%49,731.19%-6.41%1 Year Performance-65.60%-20.98%52,818.84%-2.08% IRIDEX Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IRIXIRIDEX1.1625 of 5 stars$1.03+2.6%$2.00+95.1%-66.5%$17.05M$48.43M-1.53120Earnings ReportGap DownHYPRHyperfine3.65 of 5 stars$0.83+1.2%$1.33+60.2%-28.0%$60.56M$12.89M-1.46190High Trading VolumeICADiCAD0.5475 of 5 stars$2.28+2.2%N/A+32.9%$60.51M$19.61M-17.54140CTSOCytosorbents2.0572 of 5 stars$1.03+4.7%$4.67+353.1%+5.3%$56.32M$33.79M-2.86220MBOTMicrobot Medical1.6249 of 5 stars$1.60-5.9%$9.00+462.5%+18.7%$55.59MN/A-2.0020Earnings ReportTELATELA Bio2.7847 of 5 stars$1.40-4.8%$7.25+417.9%-78.2%$55.14M$68.65M-0.83120Gap UpHigh Trading VolumeAPTAlpha Pro TechN/A$5.05+0.6%N/A-19.6%$54.91M$57.84M13.65120Analyst ForecastECORelectroCore2.6852 of 5 stars$7.43-7.1%$25.50+243.2%+4.5%$53.44M$25.18M-4.0650Short Interest ↑High Trading VolumeAPYXApyx Medical2.6179 of 5 stars$1.38+9.5%N/A-4.4%$52.16M$48.10M-1.66270Gap UpINOInovio Pharmaceuticals3.8451 of 5 stars$1.88-2.1%$12.20+548.9%-87.5%$49.07M$217,756.00-0.47320TMDIFTitan MedicalN/A$0.43flatN/A+647.6%$49.04M$17.63M-0.3450 Remove Ads Related Companies and Tools Related Companies HYPR Alternatives ICAD Alternatives CTSO Alternatives MBOT Alternatives TELA Alternatives APT Alternatives ECOR Alternatives APYX Alternatives INO Alternatives TMDIF Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IRIX) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IRIDEX Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share IRIDEX With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.